Article
Amgen Appeal Will Delay Marketing of Novartis Biosimilar
The appeals court decision has ensured that Novartis cannot bring its biosimilar Zarxio (filgrastim), which provides immune support to cancer patients, to the market at least till June 3.
A US appeals court has blocked Novartis AG from selling its knockoff version of an Amgen Inc. cancer supportive-care drug in the US until the court resolves a legal fight between the rivals.
The US Court of Appeals for the Federal Circuit in Washington on May 5 granted Amgen's request for an injunction blocking Novartis' Zarxio from the US market until the court resolves Amgen's appeal of a lower-court ruling that gave the green light to Zarxio's market entry.
The new order is expected to keep Zarxio off the US market at least until June 3, when oral arguments are scheduled, though resolution of the case could take longer.
Complete news on Nasdaq: http://bit.ly/1QsTGKK
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
